jurnista 4 mg tablete s podaljšanim sproščanjem
johnson & johnson d.o.o. - hidromorfon - tableta s podaljšanim sproščanjem - hidromorfon 3,56 mg / 1 tableta - hidromorfon
jurnista 8 mg tablete s podaljšanim sproščanjem
johnson & johnson d.o.o. - hidromorfon - tableta s podaljšanim sproščanjem - hidromorfon 7,12 mg / 1 kapsula - hidromorfon
jurnista 8 mg tablete s podaljšanim sproščanjem
johnson & johnson d.o.o. - hidromorfon - tableta s podaljšanim sproščanjem - hidromorfon 7,12 mg / 1 kapsula - hidromorfon
jurnista 64 mg tablete s podaljšanim sproščanjem
tableta s podaljšanim sproščanjem - hidromorfon
jurnista 64 mg trde kapsule s podaljšanim sproščanjem
kapsula s podaljšanim sproščanjem, trda - hidromorfon
jurnista 16 mg tablete s podaljšanim sproščanjem
johnson & johnson d.o.o. - hidromorfon - tableta s podaljšanim sproščanjem - hidromorfon 14,24 mg / 1 kapsula - hidromorfon
jurnista 32 mg tablete s podaljšanim sproščanjem
johnson & johnson d.o.o. - hidromorfon - tableta s podaljšanim sproščanjem - hidromorfon 28,48 mg / 1 kapsula - hidromorfon
bimzelx
ucb pharma s.a. - bimekizumab - psoriaza - imunosupresivi - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
quviviq
idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - motnje v zvezi s spanjem in vzdrževanjem - psiholeptiki - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
sotyktu
bristol-myers squibb pharma eeig - deucravacitinib - psoriaza - imunosupresivi - treatment of moderate-to-severe plaque psoriasis in adults.